4-carboxymethoxy-3-phenylsulfonyl-2-oxo-1,2,5-oxadiazole | 1005499-20-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-carboxymethoxy-3-phenylsulfonyl-2-oxo-1,2,5-oxadiazole
• 英文别名: {[5-oxido-4-(phenylsulphonyl)-1,2,5-oxadiazol-3-yl]oxy}acetic acid；2-[[4-(Benzenesulfonyl)-5-oxido-1,2,5-oxadiazol-5-ium-3-yl]oxy]acetic acid
• CAS: 1005499-20-6
• 化学式: C₁₀H₈N₂O₇S
• 分子量: 300.249
• InChiKey: NWUKKQQQHSJWJG-UHFFFAOYSA-N

物化性质

• 沸点：
  600.1±65.0 °C(Predicted)
• 密度：
  1.69±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  141
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-carboxymethoxy-3-phenylsulfonyl-2-oxo-1,2,5-oxadiazole 在 4-二甲氨基吡啶 、 盐酸羟胺 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  一氧化氮供体型HDAC抑制剂及其制备方法和 医药用途

  摘要：

  本发明公开了新型一氧化氮供体型HDAC抑制剂及其制备方法和医药用途，产品为式（Ⅰ）、式（Ⅱ）化合物。具有抗肝癌、肺癌、乳腺癌、脑胶质瘤、结肠癌等肿瘤的效果。

  公开号：

  CN104356087B
• 作为产物：
  描述：

  呋咱氮氧化物供体 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.0h， 生成 4-carboxymethoxy-3-phenylsulfonyl-2-oxo-1,2,5-oxadiazole
  参考文献：
  名称：

  Antitumor Platinum(II) Complexes Containing Platinum-Based Moieties of Present Platinum Drugs and Furoxan Groups as Nitric Oxide Donors: Synthesis, DNA Interaction, and Cytotoxicity

  摘要：

  Six novel platinum(II) complexes 1-6 bearing different furoxan moieties as nitric oxide (NO) donors have been designed, synthesized, and characterized by elemental analysis and H-1 NMR, IR, and ESI-MS spectroscopy. The furoxan groups were introduced to the platinum complexes to release NO, which may take synergic action with the platinum-based moieties on the tumor cells. It was found that all compounds exhibited considerable cytotoxicity against human HCT-116 and SGC-7901 cell lines via DNA binding together with NO-releasing features, especially for compound 3. This finding is in accordance with the previous reports that NO hybrids show higher cytotoxicity against colon cancer cell lines compared with their parent compounds.

  DOI：

  10.1021/ic301374z

文献信息

• New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them
  申请人：De Nanteuil Guillaume

  公开号：US20090082393A1

  公开（公告）日：2009-03-26

  Compounds of formula (I): (A) m ·(B) n (I) wherein A represents an angiotensin-converting enzyme inhibitor compound containing at least one salt-forming basic function, B represents a compound containing at least one salt-forming acid function and at least one NO donor group, m represents the number of acid functions of B that have been converted to a salt and n represents the number of basic functions of A that have been converted to a salt, the bond or bonds between A and B being of the ionic type. Medicinal products containing the same which are useful in treating cardiovascular pathologies.

  式(I)的化合物：(A)m·(B)n(I)，其中A代表至少含有一个盐形成碱性功能的抑制血管紧张素转化酶的化合物，B代表至少含有一个盐形成酸性功能和至少一个NO供体基团的化合物，m代表已转化为盐的B的酸性功能的数量，n代表已转化为盐的A的碱性功能的数量，A和B之间的键或键为离子型。含有这些化合物的药品对治疗心血管病理有用。
• Design, synthesis, and biological evaluation of artemyrianolide H derivatives as potential antihepatoma agents
  作者：Tian-Ze Li、Xiao-Tong Yang、Wen-Jing Ma、Yun-Bao Ma、Feng-Jiao Li、Yong-Cui Wang、Ji-Jun Chen

  DOI：10.1016/j.bioorg.2023.106617

  日期：2023.8
• US7981920B2
  申请人：——

  公开号：US7981920B2

  公开（公告）日：2011-07-19
• CN116082284
  申请人：——

  公开号：——

  公开（公告）日：——
• Antitumor Platinum(II) Complexes Containing Platinum-Based Moieties of Present Platinum Drugs and Furoxan Groups as Nitric Oxide Donors: Synthesis, DNA Interaction, and Cytotoxicity
  作者：Jian Zhao、Shaohua Gou、Yanyan Sun、Lei Fang、Zhimei Wang

  DOI：10.1021/ic301374z

  日期：2012.10.1

  Six novel platinum(II) complexes 1-6 bearing different furoxan moieties as nitric oxide (NO) donors have been designed, synthesized, and characterized by elemental analysis and H-1 NMR, IR, and ESI-MS spectroscopy. The furoxan groups were introduced to the platinum complexes to release NO, which may take synergic action with the platinum-based moieties on the tumor cells. It was found that all compounds exhibited considerable cytotoxicity against human HCT-116 and SGC-7901 cell lines via DNA binding together with NO-releasing features, especially for compound 3. This finding is in accordance with the previous reports that NO hybrids show higher cytotoxicity against colon cancer cell lines compared with their parent compounds.